Hattie Hayes

The modifier gene therapies from Ocugen target geographic atrophy and Stargardt disease.

Researchers indicated that pediatric patients with Leber congenital amaurosis experienced improvements in vision.

The biosimilar to aflibercept (Eylea) had already received approval in the EU and US.

The UK-based company will debut the tool, called Dr.Noon CVD, at two conferences in March

Researchers from the University of Bristol recorded increased instances of inflammation in particular demographic groups

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

ViGeneron also received approval for dose escalation in the ongoing phase 1b clinical trial.

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema

The Danish Medicines Agency requested the EMA's Pharmacovigilance Risk Assessment Committee review reports on the vision-threatening condition

Trending topics and milestone stories from 2024 on Ophthalmology Times Europe

The European Commission will assess the marketing authorisation for Eydenzelt (reference product Eylea)

The PFS is approved for treatment of neovascular age-related macular degeneration, diabetic macular edema and macular edema following retinal vein occlusion.

Phenocell and Amarna Therapeutics were awarded the grant by Eureka’s Eurostars initiative, co-funded by the European Union.

The annual meeting brought announcements and insights from companies in the retina care space.

The Belgian B Corp company, founded in 2016, is partially owned by Rayner and distributed in over 20 European countries.

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field.

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Optical coherence tomography will be in all eye care services by October 2025

The annual meeting, held in Chicago, Illinois, featured new data and best practices for patient-centered care.

The Eye Care Network adds a longstanding, CME-certified conference to its live event programming

The e-poster came in 2nd place for the August Deutman award at the EURETINA Congress

Ali Erginay, MD, spoke about the important developments in retinal imaging, specifically the Red-Blue-Green (RGB) imaging modalities during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Prof Bodaghi praises the ingenuity at this year's EURETINA Innovation Spotlight (EIS)

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings. The interview took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September 19-22, 2024.

The general secretary of the European Society of Retina Specialists (EURETINA) says the future of AI is here